Barcelona– November 12, 2025 –Meta Cell Technology, a pioneer in autologous exosome science, introduces an advancement to its MCT exosome protocols: the integration of the first injectable exosome bioimplant, designed to optimize outcomes and enhance exosome bioactivity.

Exo-Tech transforms the patient’s plasma into an injectable, viscoelastic scaffold enriched with MCT exosomes prepared using the MCT System. The result is a next-generation exosome bioimplant that provides structural support and sustained regenerative signaling.

 

 

 

A New Standard in Exosome Delivery

 

Exo-Tech creates a structured protein scaffold that acts as a local reservoir, gradually releasing exosomes and growth factors over time—prolonging regenerative activity at the target site.

Together, the MCT System and Exo-Tech deliver an injectable exosome bioimplant: a PPP-derived scaffold that retains exosomes locally, amplifies regenerative signaling, and enhances skin quality with natural, long-lasting outcomes.

 

Discover more: The First Exosome Bioimplant

 

Related on MCT: Webinar: Exo-Tech, the exosome bioimplant technology | Injectable scaffolds: Exo-Tech and the MCT System

MCT System

Bring photothermal biomodulation to your regenerative practice

The MCT System preconditions autologous PRP with controlled light and temperature, within the same clinical session.

Talk to our team Discover the MCT System → Read the published evidence →